Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of “Hold” from Analysts

Shares of Opexa Therapeutics, Inc. (NASDAQ:ACER) have earned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.

Zacks has also assigned Opexa Therapeutics an industry rank of 104 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine raised shares of Opexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd.

Opexa Therapeutics (NASDAQ:ACER) opened at $14.81 on Wednesday. Opexa Therapeutics has a 52-week low of $5.69 and a 52-week high of $22.63.

Opexa Therapeutics (NASDAQ:ACER) last issued its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter.

TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/06/opexa-therapeutics-inc-acer-receives-average-recommendation-of-hold-from-analysts.html.

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Get a free copy of the Zacks research report on Opexa Therapeutics (ACER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Opexa Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opexa Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit